Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis

Luis Carreto, Meghan Morrison, Jackie Donovan, Simon Finch, Gan Liang Tan, Tom Fardon, Robert Wilson, Elisabeth Furrie, Michael Loebinger, James D. Chalmers (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)
36 Downloads (Pure)


Alpha-1 antitrypsin deficiency (AATD) is a cause of bronchiectasis. Guidelines for bronchiectasis from the British Thoracic Society do not recommend to routinely test patients for AATD. In contrast, guidelines for AATD recommend routine screening. This contradiction, in part, results from the lack of data from large studies performing comprehensive screening. We screened 1600 patients with bronchiectasis at two centres in the UK from 2012 to 2016. In total, only eight individuals with AATD were identified representing 0.5% of the overall population. We conclude that routine screening for AATD in bronchiectasis in the UK has a low rate of detection. Further studies are required in different geographical regions, which may have a higher prevalence of AATD.

Original languageEnglish
Pages (from-to)592-593
Number of pages2
Issue number7
Early online date17 Apr 2020
Publication statusPublished - 26 Jun 2020


  • alpha1 antitrypsin deficiency
  • bronchiectasis
  • clinical epidemiology

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis'. Together they form a unique fingerprint.

Cite this